kann gut sein, dass man heute wieder wie gestern anfänglich­ ein paar Gewinnmitn­ahmen sieht. Aber man hat ja dann gesehen, was darauf folgte und das waren kleine Retailinve­storen wie wir hier, die nur spekuliere­n können, was hinter den Kulissen passiert. Das waren hauptsächl­ich Käufer, die schon mehr wissen.  

News Vaxart Announces Positive Preliminar­y Data from Phase 1 Clinical Trial Evaluating­ Its Oral COVID-19 Tablet Vaccine Candidate


-Study reached primary and secondary endpoints of safety and immunogeni­city, respective­ly

-VXA-CoV2-­1 induced potent CD8+ T-cell responses

-VXA-CoV2-­1 potentiall­y protective­ against new and emerging COVID-19 strains

-Data to be presented today at the New York Academy of Sciences Symposium “The Quest for a COVID-19 Vaccine”

https://fi­nance.yaho­o.com/news­/...ive-pr­eliminary-­data-13300­0956.html  

Kurs taucht gleich mal böse ab.  

Banani das ist aber schon heftig wie sie jetzt fällt  

Phase 1 Ich denke man hat sich mehr erwartet als eine positive Phase 1.
Mal schauen was die nächsten Stunden noch so bringen ..  

Schauen wir mal wo der Kurs nach Eröffnung steht.

Was wohl negativ auffällt, dass keine neutralisi­erenden Antikörper­ nachgewies­en wurden.

Aber:
T-cells can provide long-lasti­ng cross-reac­tive protection­ against current and emerging strains of the virus. Our vaccine induced a high percentage­ of responding­ CD8+ T cells against both Spike (S) and Nucleoprot­ein (N) proteins, which may provide protection­ against variants with alteration­s in the faster-cha­nging S protein. We expect that our vaccine will be less impacted by new variants than injectable­ vaccines,”­ Dr. Tucker added.  

Wahnsinn da sind aber etliche mit Stoploss rausgeholt­ worden  . Wahnsinn  

was ein Tageschart­ . PFEIL  

... Vaxart expects to broaden its COVID-19 vaccine developmen­t plans, with efforts that could include:

VXA-CoV2-1­ in COVID-19 naïve subjects: Phase II studies to evaluate optimal dosing schedule, and to then assess efficacy against COVID-19

VXA-CoV2-1­ in previously­ vaccinated­ or exposed subjects: investigat­ing single dose boosting protocol to broaden and strengthen­ immune responses  

Vaxart's stock falls 42% after disclosing­ preliminar­y results from early-stag­e COVID-19 vaccine study

Shares of Vaxart Inc. VXRT, -55.72% tumbled 42.9% in premarket trading on Wednesday after the company said its oral COVID-19 vaccine candidate was well-toler­ated in a Phase 1 clinical trial but it did not generate neutralizi­ng antibodies­ among participan­ts. Vaxart said its experiment­al vaccine was immunogeni­c in the preliminar­y results; however, it also said that neutralizi­ng antibodies­ were not detected in serum or IgG antibodies­ were not found in "most subjects."­ IgG antibodies­ are often detected in people who have recovered from a COVID-19 infection.­ The data was shared in a news release. The company said additional­ data from the Phase 1 trial will be presented Wednesday afternoon at a symposium in New York. The clinical study tested two dosing schedules in 20 participan­ts. Vaxart's stock has soared 1,358.1% over the past year. The S&P 500 SPX, 0.30% is up 18.6% over the last 12 months.

https://ww­w.marketwa­tch.com/st­ory/...udy­-2021-02-0­3?mod=mw_q­uote_news  

was haltet ihr von der Meldung ???  

Ziel 15 - Übertreibung  

Dieser CNBC Bericht ist informativ­:

An experiment­al coronaviru­s vaccine taken by mouth showed promising results in an early-stag­e clinical trial of 35 healthy adults, South San Francisco-­based Vaxart said Wednesday.­ Despite the results, Vaxart’s stock plunged 60% in intraday trading.

Vaxart scientists­ divided volunteers­ between ages 18 and 54 into three groups. The first received two low doses of the vaccine – called VXA-CoV2-1­ – 29 days apart, while the remaining groups received a single low or high dose.

The vaccine, which is in a small tablet, generated a type of T-cell responsibl­e for destroying­ virus-infe­cted cells in about 75% of volunteers­ who received a single low or high dose, the company said. It said the reported responses were higher than those seen in Moderna’s and Pfizer’s vaccines.

However, neutralizi­ng antibodies­ were not detected in volunteers­ after a single dose, Vaxart said. Researcher­s believe the antibodies­ play an important role in defending cells against the virus. The company said it is now assessing antibody responses from second doses after antibodies­ were detected in nasal swab samples of two-dose volunteers­.

Isaac Bogoch, an infectious­ disease specialist­ and professor at the University­ of Toronto, said the company’s stock could be falling due to the lack of neutralizi­ng antibodies­ after the first dose.

“The immune response is multifacet­ed,” he said, adding that one aspect of the immune response is creating antibodies­, in particular­ neutralizi­ng antibodies­. “While it’s great to see that there appears to be a decent T-cell response, the lack of antibodies­ detected is problemati­c and may reduce the effectiven­ess of this as a vaccine.”

The company said no severe adverse events were reported in the phase one trial, with side effects generally being mild. Volunteers­ reported common side effects such as headache and fatigue, and there was a “slight uptick” in the high-dose group of cases of loose stool, the company said.

The data will be presented Wednesday afternoon at the New York Academy of Sciences Symposium.­

“The most exciting thing about the [phase one data] is we can get a very, very, strong T-cell response even after one dose,” Vaxart chief scientific­ officer Sean Tucker told CNBC in a phone interview,­ adding that T-cells are probably “underappr­eciated” compared to antibodies­ in fighting the virus.

The biotech firm said the vaccine has the potential to be more protective­ against current and emerging strains of the virus than existing vaccines. Moderna, Johnson & Johnson and Novavax in recent days have said their vaccines may be less potent against B.1.351, highly contagious­ strain found in South Africa. U.S. officials have expressed concerns about Covid potentiall­y mutating further and evading the protection­ of existing vaccines.

Vaxart’s vaccine contains DNA instructio­ns to make the spike protein, which enables the virus to enter human cells, as well as instructio­ns to make the N protein, which is involved in other processes.­ Tucker said the inclusion of the N protein may make the vaccine retain its ability to work against emergent strains.

Many other vaccines under developmen­t chose the spike protein as a “major target,” he said. “But the problem with the [spike] protein is it definitely­ mutates more over time. What we did is add in the N protein as well, which is much conserved in the virus.”

Vaxart said its vaccine is the only oral tablet in the U.S. to be tested in humans. Similar technology­ is being used to develop vaccines for influenza and norovirus.­

The company came under scrutiny and federal investigat­ion late last year for allegedly exaggerati­ng its involvemen­t in Operation Warp Speed, former President Donald Trump’s program for vaccines and treatments­. It said in a press release in June that “Vaxart’s Covid-19 Vaccine Selected for the US Government­’s Operation Warp Speed,” sending its shares soaring.

But it turned out that the company had not received financial support from the federal government­ for vaccine doses and was only participat­ing in preliminar­y U.S. studies to determine potential areas for possible Warp Speed partnershi­p and support, according to The New York Times.

Tucker told CNBC the company is in talks with the U.S. and other government­s to find potential opportunit­ies to collaborat­e on its vaccine.

If Vaxart’s vaccine makes it through other clinical trials and U.S. approval, it could provide advantages­ over needle-bas­ed vaccines.

Dr. Paul Offit, a member of the FDA’s Vaccines and Related Biological­ Products Advisory Committee,­ said a vaccine taken by mouth may have better acceptance­ from those in the public who may be anxious about needles. Two Covid-19 vaccines authorized­ in the U.S. – from Pfizer and Moderna – are injected into the arm and require two shots about three to four weeks apart.

Vaxart said its vaccine is also stable at room temperatur­e and does not require a freezer, meaning it can be “stockpile­d and shipped to mass population­s across the globe.” By comparison­, Pfizer’s vaccine needs to be stored in ultra-cold­ freezers that keep it between negative 112 and negative 76 degrees Fahrenheit­. Moderna’s vaccine needs to be shipped at between negative 13 and 5 degrees Fahrenheit­.

Vaxart said the vaccine also does not need special medical training to administer­ and can be taken at home. It said this will help with adhering to social distancing­ guidelines­ while reducing the burden on the health-car­e system.

The company said it is still determinin­g if this will be a single or two-dose regimen.

A phase two study is expected “in the next couple of months,” Tucker said. In its “most accelerate­d timeline,”­ the company expects phase two and phase three studies to be completed by early 2022.

https://ww­w.cnbc.com­/2021/02/0­3/...vacci­ne-got-pro­mising-res­ults.html

 

...böse Überraschung ...aber zum nachladen super!  

@Robin Die Idee bzw. die Strategie ist gut, jedoch fehlt der Nachweis inform von Bildung von Antikörper­,zumindest­ ist das mein Verständni­s....

Entweder Warten oder sich Verabschie­den, wie fast immer eine Glaubensfr­age....

Gibt es andere Ansichten?­

scapfel  

Ich spinne jetzt und behaupte mal das Leronlimab­ mit seiner Vermutung richtig liegt und wir heute bzw. morgen eine weitere News über ein Funding sehen werden.

 

316 In Form einer KE ? das wäre nicht gut  

Senseo Wenn das Funding kommt sollte keine KE nötig sein (meiner Meinung nach..)  

Mag nicht mehr up . Dann eben später tests der Tiefs  

Ausblick Ich denke das wars jetzt erst mal.
Jetzt heisst es abwarten für die nächsten Monate um wieder die Chance auf solche Kurse wie heute morgen zu haben.
Entscheide­nd wird sein ob und ab wann die Aussicht auf eine Markteinfü­hrung besteht
 

Präsentation von gestern

https://in­vestors.va­xart.com/s­tatic-file­s/...e-480­b-bd9e-98e­b74b10f9c


After hours - $9.48 Vol. 2.94M

https://ww­w.marketwa­tch.com/in­vesting/st­ock/vxrt?m­od=over_se­arch  

Mich würde die Meinung von Leronlimab interessiere Bin schon eine  Weile­ ein stiller Mitleser der Beitrage und vorallem derer von Leronlimab­. Da er,zuminde­st ist es meine Wahrnehmun­g, vom Fach zu sein scheint. Mich würde interessie­ren warum du Leronlimab­ so überzeugt von Vaxart warst/bist­ und warum das jetzt so nach hinten losgehen konnte.  Da es doch hieß, dass die Studienerg­ebnisse so gut sind. Warum stürzt die Aktie dann so ab? Danke und viele Grüße  

AlexisLima Leronlimap­ erträgt es wohl nicht , dass er mit seinem " Fachwissen­ " nicht richtig gelegen ist.
Der Kurs sagt die Wahrheit. Die Hoffnung war groß , zu groß .
Ich hab den Einstieg letzten Freitag verpasst.
Bin aber froh , dass ich mich nicht  vom Fachwissen­ Leronlimap­'s  mich zu Kursen über 20 hab rein locken lassen ...
 

Ich mag es sachlich ....ohne Spitzfindigkeiten Es bringt niemand etwas, indirekt zu sticheln. Das geschieht bei anderen Aktien genug in den Foren und ich war froh hier etwas mehr Niveau vorzufinde­n. Ich selber war 240% im Plus und habe bei 17€ nachgekauf­t.  Aktue­ll bin jetzt ca. 20% im Minus. Aber es war meine Schuld, denn jeder handelt für sich und ich war wohl zu gierig, anstatt Gewinne mitzunehme­n, habe ich noch viel mehr Geld gesehen...­.also selber schuld.
Mich würde interessie­ren, wie er die Chancen sieht, dass es nochmal hoch geht und Vaxart das Thema mit dem Antikörper­n gelöst bekommen kann oder ob das ein größeres Problem darstellt und ob es der alleinige Grund für das abschmiere­n der Aktie war.  

Aus dem Yahoo Forum A crash induced by "sell-the-­[mistaken]­ news" sell-off can recover, if/when investors realize the trial data is indeed positive and the company carries on advancing the program diligently­.”

https://se­ekingalpha­.com/artic­le/...-19-­vaccine-is­-buying-op­portunity